Clazakizumab for hospitalized COVID-19 patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests a drug called clazakizumab, which may reduce harmful inflammation in the lungs of people hospitalized with COVID-19. It aims to see if the drug can help patients recover better than a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You are currently hospitalized with COVID-19, confirmed by a test in the last 72 hours.
- You have signs of lung involvement, such as low oxygen levels or abnormal chest imaging.
- You have high levels of inflammation (measured by a blood test called CRP).
- You are not pregnant or breastfeeding, and you have no active tuberculosis or other serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
This study tests whether clazakizumab can reduce the risk of heart attacks or strokes in people with high levels of inflammation (measured by a blood test called hsCRP) and conditions like heart disease, obesity, diabetes, high blood pressure, or kidney disease. If you qualify, you'll receive either the study drug or a placebo to see if it helps lower your risk.
This study tests an experimental drug called clazakizumab (CSL300) to see if it can reduce inflammation and lower the risk of heart problems in people with kidney failure who are on dialysis. It may help if you have diabetes or heart disease and have high inflammation levels.
This trial tests whether donated “recovered patient” plasma (antibodies from people who had COVID-19) can improve outcomes for people hospitalized with COVID-19. It focuses on patients early in their illness who need a small amount of oxygen.
This study tests a new antibody medicine for people with COVID-19 who are at high risk of getting very sick. If you qualify, you would receive the study drug or a placebo (inactive substance) to see if it helps you recover without needing to go to the hospital.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
Hear when a new COVID-19 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.